AGP Picks
View all

Science Press Releases
Provided by AGP

Science Press Releases: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Science Press Releases.

April 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30

May 2026

Mo Tu We Th Fr Sa Su
1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

June 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

Press releases published on June 30, 2026

Musician Living with Alpha-Gal Syndrome Shares Info following RFK Jr.’s Comments on Tick-Borne Illness
an hour ago

Musician Living with Alpha-Gal Syndrome Shares Info following RFK Jr.’s Comments on Tick-Borne Illness

Indeterminate EIN Presswire
AriBio Announces Completion of Dosing in POLARIS-AD Global Phase 3 Trial of AR1001 for Early Alzheimer’s Disease
an hour ago

AriBio Announces Completion of Dosing in POLARIS-AD Global Phase 3 Trial of AR1001 for Early Alzheimer’s Disease

Indeterminate EIN Presswire
Dr. Rao's Hospital Strengthens Multidisciplinary Neuro-Oncology Care in South India
2 hours ago

Dr. Rao's Hospital Strengthens Multidisciplinary Neuro-Oncology Care in South India

Indeterminate EIN Presswire
UNMIRI Launches a Literature Intelligence Platform for Oncology Medical Affairs
7 hours ago

UNMIRI Launches a Literature Intelligence Platform for Oncology Medical Affairs

Indeterminate EIN Presswire
Addex Shareholders Approve All Resolutions at Annual General Meeting
2 hours ago

Addex Shareholders Approve All Resolutions at Annual General Meeting

Indeterminate GlobeNewswire
WISeKey Shareholders Approved All Agenda Items of the 2026 Annual General Meeting
2 hours ago

WISeKey Shareholders Approved All Agenda Items of the 2026 Annual General Meeting

Indeterminate GlobeNewswire
Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study
2 hours ago

Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study

Indeterminate GlobeNewswire
Communiqué de presse : Le Nexviazyme de Sanofi a atteint tous les critères d’évaluation principaux et secondaires dans une étude de phase III sur la forme infantile de la maladie de Pompe
2 hours ago

Communiqué de presse : Le Nexviazyme de Sanofi a atteint tous les critères d’évaluation principaux et secondaires dans une étude de phase III sur la forme infantile de la maladie de Pompe

Indeterminate GlobeNewswire
Digital Realty Prices Secondary Offering of Common Stock by Blackstone
2 hours ago

Digital Realty Prices Secondary Offering of Common Stock by Blackstone

Indeterminate GlobeNewswire
AIPOCH Launches MedSkillAudit, an AI Audit Framework to Evaluate Medical AI Agent Skills Before Deployment
4 hours ago

AIPOCH Launches MedSkillAudit, an AI Audit Framework to Evaluate Medical AI Agent Skills Before Deployment

Indeterminate GlobeNewswire
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
4 hours ago

Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock

Indeterminate GlobeNewswire
Solulu Tech Expands Stablecoin Infrastructure to Support Cross-Border Payments and Multi-Currency Settlement
4 hours ago

Solulu Tech Expands Stablecoin Infrastructure to Support Cross-Border Payments and Multi-Currency Settlement

Indeterminate GlobeNewswire
Autheo Introduces the Internet Operating System: A Decentralized Coordination Layer for the Web, Blockchain, and AI
5 hours ago

Autheo Introduces the Internet Operating System: A Decentralized Coordination Layer for the Web, Blockchain, and AI

Indeterminate GlobeNewswire

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Science Press Releases

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.